[3H]-RU 28362 | 74915-64-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [3H]-RU 28362
• 英文别名: RU 28362；11β,17β-dihydroxy-6,21-dimethyl-17α-pregna-1,4,6-trien-20-yn-3-one；RU28362；11,17-Dihydroxy-6-methyl-17-(1-propynyl)androsta-1,4,6-triene-3-one；(8S,9S,10R,11S,13S,14S,17S)-11,17-dihydroxy-6,10,13-trimethyl-17-prop-1-ynyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthren-3-one
• CAS: 74915-64-3
• 化学式: C₂₃H₂₈O₃
• 分子量: 352.474
• InChiKey: UFZKDKHLKHEFGA-ZFTCBNFESA-N

物化性质

• 沸点：
  533.2±50.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)
• 溶解度：
  在DMSO中的溶解度为33 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  11β,17β,21-trihydroxy-6α-methyl-4-pregnene-3,20-dione 在 sodium bismuthate 、 对甲苯磺酸 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 反应 61.25h， 生成 [3H]-RU 28362
  参考文献：
  名称：

  17α-Alkynyl-11β,17-dihydroxyandrostane derivatives : A new class of potent glucocorticoids.

  摘要：

  Replacement of the characteristic dihydroxyacetone side chain of corticoids by a 17 alpha-alkynyl-17 beta-hydroxy moiety was investigated. It was found that, in particular, the 17 alpha-propynyl substitution is favorable for high local anti-inflammatory activity with reduced systemic effects. Moreover, these compounds were found to be devoid of any affinity for the aldosterone receptor, and may thus be considered as pure glucocorticoids.

  DOI：

  10.1016/0039-128x(81)90084-2

文献信息

• [EN] NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II<br/>[FR] NOUVEAUX COMPOSÉS UTILES DANS LE TRAITEMENT ET/OU LA PRÉVENTION D'UNE MALADIE, D'UN TROUBLE OU D'UN ÉTAT DE SANTÉ ASSOCIÉ À L'ANGIOTENSINE II
  申请人：VICORE PHARMA AB

  公开号：WO2021186185A1

  公开（公告）日：2021-09-23

  The present disclosure relates to compounds of Formula (I) and to their utility in the treatment in a disease, disorder and/or condition associated with the peptide angiotensin II.

  本公开涉及I式化合物及其在治疗与肽血管紧张素II相关的疾病、紊乱和/或病况中的效用。
• [EN] SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS<br/>[FR] LIGANDS SÉLECTIFS DU RÉCEPTEUR DE L'ANGIOTENSINE II
  申请人：VICORE PHARMA AB

  公开号：WO2022200785A1

  公开（公告）日：2022-09-29

  There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R6, X, Y, Z, Y1, Y2, Y3and Y4have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

  提供了式子I的药物化合物，其中R1、R2、R3、R4、R6、X、Y、Z、Y1、Y2、Y3和Y4的含义在说明中给出，这些化合物在治疗自身免疫和/或纤维化疾病方面有用，包括间质性肺病，如特发性肺纤维化和结节病。
• Stéroides radioactifs, leur procédé et leurs intermédiaires de préparation, leur application à la mise en évidence des récepteurs de glucocorticoides et au dosage du nombre de sites de fixation
  申请人：ROUSSEL-UCLAF

  公开号：EP0128839B1

  公开（公告）日：1989-05-17
• FORMULATIONS AND DOSES OF PEGYLATED URICASE
  申请人：Selecta Biosciences, Inc.

  公开号：EP3980784A1

  公开（公告）日：2022-04-13
• METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTIINFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT
  申请人：Johnston Lloyd

  公开号：US20180289776A1

  公开（公告）日：2018-10-11

  Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.